Drug Search Results
More Filters [+]

PRTH-101

Alternative Names: PRTH-101, PRTH101, PRTH 101
Latest Update: 2024-05-23
Latest Update Note: News Article

Product Description

Mechanisms of Action: DDR1 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Incendia Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PRTH-101

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PRTH-101-0001

P1

Recruiting

Oncology Solid Tumor Unspecified

2027-09-30

Recent News Events